Pentax Medical, a division of Hoya Group, has introduced new bipolar hot hemostasis forceps to support early treatment of gastric cancer.
The HemoStat WideCup device will enable to control bleeding during endoscopic therapy procedures.
The company will exhibit the device at JDDW 2016 Congress, which is being held from 3 to 6 November in Kobe of Japan.
Flexible endoscopes, along with therapeutic devices, will be used in minimally invasive treatment procedures.
HemoStat WideCup offers easy grip for bleeding point and less handling power for easy operation/
Pentax Medical global president Gerald Bottero said: ““Pentax Medical is commited to strengthening our endoscopic therapy portfolio to support better patient care.
“The HemoStat WideCup is a highly innovative hemostasis device designed to greatly simplify the control of bleeding.
‘We are confident the HemoStat WideCup sets a new standard for precise, efficient and safer endoscopic therapy, and will further support global growth of early screening and treatment of gastric cancer.”
In June, Pentax Medical launched new Defina endoscopy system, which is designed for ENT diagnosis. It is available in the European, Middle Eastern & African (EMEA) markets.
The system can be used in a range of ENT applications and provides fiberoptic endoscopic evaluation of swallowing (FEES) and functional video stroboscopy examinations.
Pentax Medical offers endoscopic imaging devices and solutions to its medical customers.
Image: Pentax Medical launches new bipolar hot hemostasis forceps. Photo: courtesy of PENTAX Medical.